.png){kind=logo}
US-based sterile injectable (pre-filled syringe) manufacturing facility focused on small-molecule generic 505b2 and 505j products.
Minimally-invasive nitinol implant delivered into prostatic urethra and indicated to re-open the prostatic urethra in BPH patients, restoring urinary flow.
HOW WE USE YOUR INFORMATION
-
to operate, manage, develop and promote our business and, in particular, our relationship with you and the organization you represent (if any) and related investments and/or transactions;
-
to operate, administer and improve our website and premises and other aspects of the way in which we conduct our operations;
-
to protect our business from fraud, money-laundering, breach of confidence, theft of proprietary materials and other financial or business crimes;
-
to send marketing communications to you, if applicable and
-
to comply with our legal and regulatory obligations and bring and defend legal claims.
​
We may review information about you that we maintain in our systems, including the contents of and information related to your emails and other communications with us, for compliance and business-protection purposes as described above. This may include reviews to disclose information relevant to litigation and/or reviews of records relevant to internal or external regulatory or criminal investigations. To the extent permitted by applicable law, these reviews will be conducted in a reasonable and proportionate way and approved at an appropriate level of management. They may ultimately involve the disclosure of your information to governmental agencies and litigation counterparties as described below. Your emails and other communications may occasionally be accessed by persons other than the staff member with whom they are exchanged for ordinary business management purposes (for example, where necessary when a staff member is out of the office or has left New Rhein). 
​
We will only use your personal information for the purposes for which we collected it, unless we reasonably consider that we need to use it for another reason and that reason is compatible with the original purpose. If you wish to get an explanation as to how the processing for the new purpose is compatible with the original purpose, please contact us.
​
If we need to use your personal information for an unrelated purpose, we will notify you and we will explain the legal basis which allows us to do so.
SHANKAR HARIHARAN, PHD
Dr. Hariharan is the Executive Vice President and Chief Scientific Officer at Amneal Pharmaceuticals, Inc. At Amneal, Dr. Hariharan oversees Research & Development, Regulatory Affairs, and Specialty Pharmaceutical Dosage Development. Dr. Hariharan has over 30 years of experience in successfully leading branded and generic pharmaceutical businesses and has held leadership positions at companies including International Development Research, Forest Labs, and Par Pharmaceuticals. Prior to joining Amneal, Dr. Hariharan founded DermAct, an R&D organization specializing in dermatology. Dr. Hariharan completed his bachelor’s degree in pharmacy at Banaras Hindu University in India and his doctorate in pharmacy at Northeastern University in Boston, Massachusetts.
SHANKAR HARIHARAN, PHD
Dr. Hariharan is the Executive Vice President and Chief Scientific Officer at Amneal Pharmaceuticals, Inc. At Amneal, Dr. Hariharan oversees Research & Development, Regulatory Affairs, and Specialty Pharmaceutical Dosage Development. Dr. Hariharan has over 30 years of experience in successfully leading branded and generic pharmaceutical businesses and has held leadership positions at companies including International Development Research, Forest Labs, and Par Pharmaceuticals. Prior to joining Amneal, Dr. Hariharan founded DermAct, an R&D organization specializing in dermatology. Dr. Hariharan completed his bachelor’s degree in pharmacy at Banaras Hindu University in India and his doctorate in pharmacy at Northeastern University in Boston, Massachusetts.
SHANKAR HARIHARAN, PHD
Dr. Hariharan is the Executive Vice President and Chief Scientific Officer at Amneal Pharmaceuticals, Inc. At Amneal, Dr. Hariharan oversees Research & Development, Regulatory Affairs, and Specialty Pharmaceutical Dosage Development. Dr. Hariharan has over 30 years of experience in successfully leading branded and generic pharmaceutical businesses and has held leadership positions at companies including International Development Research, Forest Labs, and Par Pharmaceuticals. Prior to joining Amneal, Dr. Hariharan founded DermAct, an R&D organization specializing in dermatology. Dr. Hariharan completed his bachelor’s degree in pharmacy at Banaras Hindu University in India and his doctorate in pharmacy at Northeastern University in Boston, Massachusetts.
Nishant Rastogi
Vice President, Head of Transactions
Nishant joined New Rhein in 2018 and leads the Fund’s Transactions team. He is a founding member of the Philadelphia office and helped launch the firm’s funds in 2018 and 2021. He is responsible for search and evaluation of new opportunities, due diligence, negotiation and execution of investments, and portfolio management. Prior to New Rhein, Nishant was an investor at Broadview Ventures, and an analyst at Fidelity Investments.
Nishant has screened thousands of private biotech, pharma, and medical device companies - ranging from early-stage academic start-ups to late-clinical stage and commercial technologies. He has experience leading assessments across geographies, stages of development, and functional areas - including scientific, clinical, regulatory, commercial, CMC, IP, corporate, and financial due diligence, with expert support.
​
At New Rhein, he has been involved in the investment of Fund '18 and Fund '21 into 8 portfolio companies. Post-investment, his experience includes board involvement, company creation, executive recruitment, capital raising / business development, and supporting the achievement of regulatory and commercial milestones. He is involved in New Rhein’s investments in Softhale, Neuraptive, American Injectables, Butterfly Medical, Saayva, Theranica, Corsair, and Alveus.
​
At Broadview, Nishant was involved in investments in FineHeart, InfoBionic, Apama Medical, Gila Therapeutics, and others. He contributed to a publication in the Journal of the American College of Cardiology in 2016 on the importance of impact investing in life sciences. Currently, he serves as an advisor to the Beyond Celiac Foundation and The Parent Project Muscular Dystrophy Foundation on venture philanthropy and fund formation.
​
Nishant received his MBA from Northwestern University and his BA in Economics from Dartmouth College. He also completed post-graduate coursework in medical science from Harvard. He currently resides in Princeton, NJ.